Cencora, Inc. (NYSE: COR) today announced that its Board of Directors has elected Robert E. Sanchez as a new independent director, effective October 1, 2026.
Cencora (NYSE:COR) executives said the company expects its specialty-focused strategy to support continued growth into fiscal 2027, citing demand in oncology and retina, expanded physician-services capabilities and momentum in its international businesses.
Speaking at the Morgan Stanley Global Heal
Cencora (NYSE:COR) executives highlighted the company’s specialty pharmaceutical positioning, medical specialty organization strategy and capital-allocation priorities during an investor conference discussion, while reaffirming the durability of its relationship with Walgreens.
Chief Executive Offi
Cencora (NYSE:COR) has outperformed the market over the past 10 years by 6.79% on an annualized basis producing an average annual return of 20.35%. Currently, Cencora has a market capitalization of $61.36 billion.
The S&P 500 (^GSPC) is home to the biggest and most well-known companies in the market, making it a go-to index for investors seeking stability. But not all ...
Earnings results often indicate what direction a company will take in the months ahead. With Q2 behind us, let’s have a look at Cencora (NYSE:COR) and its pe...
Cencora (NYSE:COR) has outperformed the market over the past 10 years by 6.61% on an annualized basis producing an average annual return of 19.99%. Currently, Cencora has a market capitalization of $60.51 billion.
Cencora (NYSE:COR) has outperformed the market over the past 10 years by 6.29% on an annualized basis producing an average annual return of 19.83%. Currently, Cencora has a market capitalization of $59.16 billion.
Cardinal Health stock hit a new all-time high after mixed earnings, with analyst price target hikes, gene therapy logistics wins and a 29-year dividend growth streak supporting the uptrend.
Cencora’s second quarter was marked by performance that met Wall Street’s expectations on revenue and exceeded consensus on non-GAAP profitability, driving a...
Cencora (NYSE:COR) reported fiscal 2026 third-quarter results marked by double-digit adjusted operating income growth, specialty-business momentum and $1 billion in share repurchases, prompting the pharmaceutical services company to raise its full-year adjusted earnings outlook.
Adjusted operating
Healthcare distributor Cencora (NYSE:COR) met Wall Street’s revenue expectations in Q2 CY2026, with sales up 5.1% year on year to $84.75 billion. Its non-GAA...
Healthcare distributor Cencora (NYSE:COR) met Wall Street’s revenue expectations in Q2 CY2026, with sales up 5.1% year on year to $84.75 billion. Its non-GAA...
Cencora, Inc. (NYSE: COR) reported that in its fiscal year 2026 third quarter ended June 30, 2026, revenue increased 5.1 percent year-over-year to $84.8 billion. On the basis of U.S. generally accepted accounting principles (GAAP), diluted earnings per share (EPS) was $3.94 for the third quarter of fiscal 2026 compared to $3.52 in the prior year third quarter. Adjusted diluted EPS, which is a non-GAAP financial measure that excludes items described below, increased 12.0 percent to $4.48 in the fiscal third quarter from $4.00 in the prior year third quarter.
Healthcare distributor Cencora (NYSE:COR) will be reporting earnings this Wednesday before market hours. Here’s what you need to know. Cencora missed analyst...
McKesson posted strong fiscal 2026 results, raised guidance, boosted buybacks and its dividend, and maintains a Moderate Buy rating from analysts amid its evolving specialty business mix.
Earnings results often indicate what direction a company will take in the months ahead. With Q1 behind us, let’s have a look at Cencora (NYSE:COR) and its pe...
